Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.
about
New viruses for cancer therapy: meeting clinical needsTrial Watch:: Oncolytic viruses for cancer therapyTrial Watch-Oncolytic viruses and cancer therapyProgress and problems with the use of suicide genes for targeted cancer therapyOncolytic viruses: From bench to bedside with a focus on safety.Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivityMicroRNA 142-3p attenuates spread of replicating retroviral vector in hematopoietic lineage-derived cells while maintaining an antiviral immune response.Tomato thymidine kinase-based suicide gene therapy for malignant glioma--an alternative for Herpes Simplex virus-1 thymidine kinase.Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector.Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma modelIncreased sensitivity of glioma cells to 5-fluorocytosine following photo-chemical internalization enhanced nonviral transfection of the cytosine deaminase suicide geneMaintaining therapeutic activity in the operating room: compatibility of a gamma-retroviral replicating vector with clinical materials and biofluids.Advancements in the development of HIF-1α-activated protein switches for use in enzyme prodrug therapy.Photodynamic therapy enhances the efficacy of gene-directed enzyme prodrug therapy.EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMARetroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.Extensive Replication of a Retroviral Replicating Vector Can Expand the A Bulge in the Encephalomyocarditis Virus Internal Ribosome Entry Site and Change Translation Efficiency of the Downstream Transgene.Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor modelGlioma virus therapies between bench and bedside.Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brainRetroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In VitroClinical trials of viral therapy for malignant gliomas.Targeting tumor suppressor genes for cancer therapy.Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.Oncolytic Immunotherapy for Treatment of Cancer.Gene Delivery in Neuro-Oncology.Retroviral replicating vector-mediated gene therapy achieves long-term control of tumor recurrence and leads to durable anticancer immunity.Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.Oncolytic virotherapy for gliomas: steps toward the future.Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer Models.Industry progress report on neuro-oncology: Biotech update 2013.Biotransporting Self-Assembled Nanofactories Using Polymer Vesicles with Molecular Permeability for Enzyme Prodrug Cancer Therapy.White paper on microbial anti-cancer therapy and prevention
P2860
Q24567699-8331E93B-E319-4841-90F3-E9A7E160D615Q27021951-B61CFCFA-9644-4FD1-85B5-50BAC5F48F30Q28072347-9B44311F-1D19-494F-8CB6-0E3689BA299EQ28262370-9CE62901-BE9C-49EF-8AB5-432D1A23BEF8Q34044071-F97DD43E-5ED3-415D-9263-5933CF81581FQ34059493-FF27C54B-ACB5-47E4-BDBE-5BC2A80342B0Q34063551-8F11CD74-E1BB-4C14-9926-166C2B3F0E4EQ34459264-14B94E14-B4D5-4C54-8C51-B1D172B7A74AQ34580201-14F85C89-CF49-446E-82E9-45874BCD07BFQ35077635-7B2600B4-78E5-4EA2-9A96-8CB5D7D73B0DQ35115061-7A34A10D-0929-417B-BC0D-6B5261F240ECQ35184172-D7AEEEB1-C776-438A-918D-97718410F991Q35451950-E618D710-0B9E-4D4C-86F6-E03A462D95DBQ36297034-3158BFEB-BAD1-4A35-9FE3-8496339D7BECQ36549443-2BFFF83D-295F-4481-A9BC-11EED06FDFFCQ36602123-D245E58D-A3B7-4F8F-88AE-5EBDA77EBF92Q36806369-D30134BE-4DB1-45C5-844F-DA3D9C3055DAQ37069887-DF0B9C10-5B78-4D93-A21B-4B403747E951Q37580510-E0EF5996-A611-4164-86A4-FD864287C00AQ37610904-C68BB864-4F46-4C73-BE9C-7625606E5F22Q37718077-F1DBC38C-32C4-43C7-9974-64208842870FQ38153777-BBFEED74-92C6-45E4-B61B-F631589876D6Q38601568-031A7D3E-EE85-4597-971B-D24767A28726Q38733637-99BE2FCE-1280-4172-9226-D776ACDE9DEAQ38848060-4B8850DF-15F7-4EF0-B4EB-B752162DE685Q38848223-41D6A232-DA3E-4B8D-9CDA-0A4DEDB9B80BQ40060078-151C7611-AFC9-481C-9C1E-E0AFDA5A399DQ40253347-1F24D16A-57A6-455C-A008-6BAF9C4CBA7DQ40760304-77427F26-A071-4A86-ACD6-36B54D6AC5AEQ42274901-FCB4B417-57A4-4804-9F4C-1AD2E38920C7Q43436260-86A06C61-6946-4494-B64D-743358A46AFCQ45939742-09EB2C2F-CDB4-4E4E-97F4-BCC2895CE0C4Q47739279-E8DEF832-163E-4220-9758-6453B25F2BFDQ47771059-0868FBA2-7D7D-416C-91C8-4F917DFB3241Q47917107-9E5CCBEF-CE31-45C9-92F8-9A2FC66849FAQ56898750-6F33FDD8-A0B9-44B1-913D-8228EF525A85
P2860
Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Design and selection of Toca 5 ...... stability and gene expression.
@ast
Design and selection of Toca 5 ...... stability and gene expression.
@en
type
label
Design and selection of Toca 5 ...... stability and gene expression.
@ast
Design and selection of Toca 5 ...... stability and gene expression.
@en
prefLabel
Design and selection of Toca 5 ...... stability and gene expression.
@ast
Design and selection of Toca 5 ...... stability and gene expression.
@en
P2093
P2860
P356
P1433
P1476
Design and selection of Toca 5 ...... stability and gene expression.
@en
P2093
Akihito Inagaki
Carlos Ibanez
Cindy Burrascano
Dawn Jolson
Douglas J Jolly
Harry E Gruber
Karin Amundson
Kei Hiraoka
P2860
P304
P356
10.1038/MT.2012.83
P577
2012-05-01T00:00:00Z